Objective: The main objective of this study is to identify clinical and pathological factors associated with recurrence in patients diagnosed with early-stage (stage I–II) endometrial cancer.Methods: A total of 98 patients diagnosed with stage I–II endometrial cancer who underwent surgical treatment at a single center between 2017 and 2021 were retrospectively analyzed. The patients’ clinical and pathological characteristics, the adjuvant therapies administered, and follow-up outcomes were evaluated. Factors associated with recurrence were assessed using univariate analyses.Results: The mean age of the patients was 59.8 years, and the mean tumor size was 3.58 cm. The mean follow-up period was 49.1 months. The recurrence rate was 8.2%. Five recurrences were identified as locoregional, and three as distant metastases. In univariate analyses, surgical type (p=0.015), adjuvant therapy (p=0.009), and histotype (endometrioid vs. non-endometrioid, p=0.016) were found to be associated with recurrence.Conclusions: The recurrence rate in early-stage endometrial cancer was found to be low, consistent with the literature, and it was determined that 5 of the recurrences were locoregional in nature, while the remaining 3 were distant metastases. Although surgical type, histological type, and adjuvant therapy were identified as factors associated with recurrence in univariate analyses, there is a need for a detailed examination of these factors through multicenter studies involving larger patient cohorts.
Yalçın et al. (Fri,) studied this question.